Study Targeting Affect Regulation (STAR)
|ClinicalTrials.gov Identifier: NCT01237366|
Recruitment Status : Completed
First Posted : November 9, 2010
Last Update Posted : October 27, 2014
|Condition or disease||Intervention/treatment||Phase|
|HIV AIDS Substance Use Disorders||Behavioral: Resilient Affective Processing Therapy (RAPT)||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||56 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Pilot RCT of Expressive Writing With HIV-Positive Methamphetamine Users|
|Study Start Date :||September 2010|
|Primary Completion Date :||January 2013|
|Study Completion Date :||May 2014|
|Experimental: Reslient Affective Processing Therapy (RAPT)||
Behavioral: Resilient Affective Processing Therapy (RAPT)
Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
No Intervention: Attention-Control
Participants will complete 7 sessions where they will be asked to write about neutral topics and complete psychological measures for the purposes of matching for attention and reimbursement.
- Traumatic stress symptom severity [ Time Frame: 3-month follow-up ]Our team will use the Impact of Event Scale to measure the self-reported severity of traumatic stress symptoms related to HIV/AIDS.
- Psychological reactivity to expressive writing [ Time Frame: 1-month follow-up ]Participants will complete measures of subjective distress and craving of stimulants (i.e., methamphetamine, cocaine, and crack) before and after each expressive writing exercise to provide an index of habituation. Habituation is defined as a 50% reduction in the psychological reactivity to the expressive writing experience using these self-report measures.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01237366
|United States, California|
|UCSF Center for AIDS Prevention Studies|
|San Francisco, California, United States, 94105|
|Principal Investigator:||Adam Carrico, PhD||University of California, San Francisco|